ParkinsonCanadaV1, PascalFrancis, Curation, bibRecord, 000044

Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice

Identifieur interne : 000044 ( PascalFrancis/Curation ); précédent : 000043; suivant : 000045

Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice

Auteurs : M. Grandbois [Canada] ; M. Morissette [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada]

Source :

Neuroreport : (Oxford) [ 0959-4965 ] ; 2000.

RBID : Pascal:00-0365236

Descripteurs français

Pascal (Inist)
- Modèle animal, Parkinson maladie, Voie dopaminergique, Mâle, Estradiol, Encéphale, Animal, Souris, Souris C57BL/6.

English descriptors

KwdEn :
- Animal, Animal model, Brain (vertebrata), Dopaminergic pathway, Estradiol, Male, Mouse, Parkinson disease.

Abstract

The activity of steroids was studied in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioned retired breeder C57BL/6 male mice as a model of Parkinson's disease. Steroids were injected daily for 5 days before MPTP (4 injections, 15 mg/kg i.p;, at 2 h intervals) and hormonal treatment continued for 5 more days. Mice that received 17β-estradiol or progesterone or raloxifene (a selective estrogen receptor modulator) and MPTP had striatal concentrations of dopamine (DA) and its metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) similar to those in control animals, whereas mice that received MPTP alone or with 17α-estradiol (the isomer with weak estrogenic activity) has an extensive decrease of DA and its metabolites. These results suggest stereospecific prevention of MPTP-induced dopamine loss by 17β-estradiol, which is also observed with progesterone and raloxifene.

A01	`01`	`1`		`@0 0959-4965`
A03		`1`		`@0 Neuroreport : (Oxf.)`
A05				`@2 11`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice`
A11	`01`	`1`		`@1 GRANDBOIS (M.)`
A11	`02`	`1`		`@1 MORISSETTE (M.)`
A11	`03`	`1`		`@1 CALLIER (S.)`
A11	`04`	`1`		`@1 DI PAOLO (T.)`
A14	`01`			`@1 Oncology and Molecular Endocrinology Research Center, Laval University Medical Center (CHUL), 2705, Laurier boulevard @2 Sainte-Foy, Quebec, PQ, G1V 4G2 @3 CAN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A14	`02`			`@1 Faculty of Pharmacy, Laval University @2 Quebec, PQ, G1K 7P4 @3 CAN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A14	`03`			`@1 INSERM Unit 339, St-Antoine Hospital @2 75012 Paris @3 FRA @Z 3 aut.`
A20				`@1 343-346`
A21				`@1 2000`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 22534 @5 354000087394280240`
A44				`@0 0000 @1 © 2000 INIST-CNRS. All rights reserved.`
A45				`@0 25 ref.`
A47	`01`	`1`		`@0 00-0365236`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Neuroreport : (Oxford)`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 The activity of steroids was studied in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioned retired breeder C57BL/6 male mice as a model of Parkinson's disease. Steroids were injected daily for 5 days before MPTP (4 injections, 15 mg/kg i.p;, at 2 h intervals) and hormonal treatment continued for 5 more days. Mice that received 17β-estradiol or progesterone or raloxifene (a selective estrogen receptor modulator) and MPTP had striatal concentrations of dopamine (DA) and its metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) similar to those in control animals, whereas mice that received MPTP alone or with 17α-estradiol (the isomer with weak estrogenic activity) has an extensive decrease of DA and its metabolites. These results suggest stereospecific prevention of MPTP-induced dopamine loss by 17β-estradiol, which is also observed with progesterone and raloxifene.
C02	`01`	`X`		`@0 002A26C03`
C03	`01`	`X`	`FRE`	`@0 Modèle animal @5 01`
C03	`01`	`X`	`ENG`	`@0 Animal model @5 01`
C03	`01`	`X`	`SPA`	`@0 Modelo animal @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinson maladie @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @5 02`
C03	`03`	`X`	`FRE`	`@0 Voie dopaminergique @5 03`
C03	`03`	`X`	`ENG`	`@0 Dopaminergic pathway @5 03`
C03	`03`	`X`	`SPA`	`@0 Vía dopaminérgica @5 03`
C03	`04`	`X`	`FRE`	`@0 Mâle @5 04`
C03	`04`	`X`	`ENG`	`@0 Male @5 04`
C03	`04`	`X`	`SPA`	`@0 Macho @5 04`
C03	`05`	`X`	`FRE`	`@0 Estradiol @2 NK @2 FR @5 05`
C03	`05`	`X`	`ENG`	`@0 Estradiol @2 NK @2 FR @5 05`
C03	`05`	`X`	`SPA`	`@0 Estradiol @2 NK @2 FR @5 05`
C03	`06`	`X`	`FRE`	`@0 Encéphale @5 06`
C03	`06`	`X`	`ENG`	`@0 Brain (vertebrata) @5 06`
C03	`06`	`X`	`SPA`	`@0 Encéfalo @5 06`
C03	`07`	`X`	`FRE`	`@0 Animal @5 54`
C03	`07`	`X`	`ENG`	`@0 Animal @5 54`
C03	`07`	`X`	`SPA`	`@0 Animal @5 54`
C03	`08`	`X`	`FRE`	`@0 Souris @5 55`
C03	`08`	`X`	`ENG`	`@0 Mouse @5 55`
C03	`08`	`X`	`SPA`	`@0 Ratón @5 55`
C03	`09`	`X`	`FRE`	`@0 Souris C57BL/6 @4 INC @5 78`
C07	`01`	`X`	`FRE`	`@0 Hormone stéroïde sexuelle @5 32`
C07	`01`	`X`	`ENG`	`@0 Sex steroid hormone @5 32`
C07	`01`	`X`	`SPA`	`@0 Hormona esteroide sexual @5 32`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central @5 35`
C07	`02`	`X`	`ENG`	`@0 Central nervous system @5 35`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso central @5 35`
C07	`03`	`X`	`FRE`	`@0 Rodentia @2 NS`
C07	`03`	`X`	`ENG`	`@0 Rodentia @2 NS`
C07	`03`	`X`	`SPA`	`@0 Rodentia @2 NS`
C07	`04`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`04`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`04`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`05`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`05`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`05`	`X`	`SPA`	`@0 Vertebrata @2 NS`
N21				`@1 248`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000C80

Links to Exploration step

Pascal:00-0365236

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice</title>
<author><name sortKey="Grandbois, M" sort="Grandbois, M" uniqKey="Grandbois M" first="M." last="Grandbois">M. Grandbois</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, Laval University Medical Center (CHUL), 2705, Laurier boulevard</s1>
<s2>Sainte-Foy, Quebec, PQ, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec, PQ, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M." last="Morissette">M. Morissette</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, Laval University Medical Center (CHUL), 2705, Laurier boulevard</s1>
<s2>Sainte-Foy, Quebec, PQ, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec, PQ, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Callier, S" sort="Callier, S" uniqKey="Callier S" first="S." last="Callier">S. Callier</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, Laval University Medical Center (CHUL), 2705, Laurier boulevard</s1>
<s2>Sainte-Foy, Quebec, PQ, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec, PQ, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>INSERM Unit 339, St-Antoine Hospital</s1>
<s2>75012 Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, Laval University Medical Center (CHUL), 2705, Laurier boulevard</s1>
<s2>Sainte-Foy, Quebec, PQ, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec, PQ, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0365236</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0365236 INIST</idno>
<idno type="RBID">Pascal:00-0365236</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C80</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000044</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice</title>
<author><name sortKey="Grandbois, M" sort="Grandbois, M" uniqKey="Grandbois M" first="M." last="Grandbois">M. Grandbois</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, Laval University Medical Center (CHUL), 2705, Laurier boulevard</s1>
<s2>Sainte-Foy, Quebec, PQ, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec, PQ, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M." last="Morissette">M. Morissette</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, Laval University Medical Center (CHUL), 2705, Laurier boulevard</s1>
<s2>Sainte-Foy, Quebec, PQ, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec, PQ, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Callier, S" sort="Callier, S" uniqKey="Callier S" first="S." last="Callier">S. Callier</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, Laval University Medical Center (CHUL), 2705, Laurier boulevard</s1>
<s2>Sainte-Foy, Quebec, PQ, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec, PQ, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>INSERM Unit 339, St-Antoine Hospital</s1>
<s2>75012 Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, Laval University Medical Center (CHUL), 2705, Laurier boulevard</s1>
<s2>Sainte-Foy, Quebec, PQ, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec, PQ, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neuroreport : (Oxford)</title>
<title level="j" type="abbreviated">Neuroreport : (Oxf.)</title>
<idno type="ISSN">0959-4965</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neuroreport : (Oxford)</title>
<title level="j" type="abbreviated">Neuroreport : (Oxf.)</title>
<idno type="ISSN">0959-4965</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Animal model</term>
<term>Brain (vertebrata)</term>
<term>Dopaminergic pathway</term>
<term>Estradiol</term>
<term>Male</term>
<term>Mouse</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Modèle animal</term>
<term>Parkinson maladie</term>
<term>Voie dopaminergique</term>
<term>Mâle</term>
<term>Estradiol</term>
<term>Encéphale</term>
<term>Animal</term>
<term>Souris</term>
<term>Souris C57BL/6</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The activity of steroids was studied in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioned retired breeder C57BL/6 male mice as a model of Parkinson's disease. Steroids were injected daily for 5 days before MPTP (4 injections, 15 mg/kg i.p;, at 2 h intervals) and hormonal treatment continued for 5 more days. Mice that received 17β-estradiol or progesterone or raloxifene (a selective estrogen receptor modulator) and MPTP had striatal concentrations of dopamine (DA) and its metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) similar to those in control animals, whereas mice that received MPTP alone or with 17α-estradiol (the isomer with weak estrogenic activity) has an extensive decrease of DA and its metabolites. These results suggest stereospecific prevention of MPTP-induced dopamine loss by 17β-estradiol, which is also observed with progesterone and raloxifene.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0959-4965</s0>
</fA01>
<fA03 i2="1"><s0>Neuroreport : (Oxf.)</s0>
</fA03>
<fA05><s2>11</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GRANDBOIS (M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MORISSETTE (M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CALLIER (S.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DI PAOLO (T.)</s1>
</fA11>
<fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, Laval University Medical Center (CHUL), 2705, Laurier boulevard</s1>
<s2>Sainte-Foy, Quebec, PQ, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec, PQ, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>INSERM Unit 339, St-Antoine Hospital</s1>
<s2>75012 Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>343-346</s1>
</fA20>
<fA21><s1>2000</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>22534</s2>
<s5>354000087394280240</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2000 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>25 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>00-0365236</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neuroreport : (Oxford)</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The activity of steroids was studied in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioned retired breeder C57BL/6 male mice as a model of Parkinson's disease. Steroids were injected daily for 5 days before MPTP (4 injections, 15 mg/kg i.p;, at 2 h intervals) and hormonal treatment continued for 5 more days. Mice that received 17β-estradiol or progesterone or raloxifene (a selective estrogen receptor modulator) and MPTP had striatal concentrations of dopamine (DA) and its metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) similar to those in control animals, whereas mice that received MPTP alone or with 17α-estradiol (the isomer with weak estrogenic activity) has an extensive decrease of DA and its metabolites. These results suggest stereospecific prevention of MPTP-induced dopamine loss by 17β-estradiol, which is also observed with progesterone and raloxifene.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A26C03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Modèle animal</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Animal model</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Modelo animal</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Voie dopaminergique</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Dopaminergic pathway</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Vía dopaminérgica</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Mâle</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Male</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Macho</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Estradiol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Estradiol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estradiol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Brain (vertebrata)</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Animal</s0>
<s5>54</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Animal</s0>
<s5>54</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Animal</s0>
<s5>54</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Souris</s0>
<s5>55</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Mouse</s0>
<s5>55</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Ratón</s0>
<s5>55</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Souris C57BL/6</s0>
<s4>INC</s4>
<s5>78</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Hormone stéroïde sexuelle</s0>
<s5>32</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Sex steroid hormone</s0>
<s5>32</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hormona esteroide sexual</s0>
<s5>32</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>35</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>35</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>35</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fN21><s1>248</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000044 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000044 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:00-0365236
   |texte=   Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice

Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri